In a recent post on the IVI-sponsored Health Affairs featured blog series, Alison Bateman-House, Kelly McBride-Folkers and Arthur Caplan discuss the Trickett Wendler Right to Try Act of 2017. The authors outline key obstacles likely to limit the effectiveness of the law and present some alternative measures for achieving access to experimental drugs for patients.

Read the full article here.

About the Health Affairs/IVI Featured Blog Series: Drugs and Medical Innovation — In partnership with Health Affairs, IVI is proud to sponsor the “Drugs and Medical Innovation” blog series. On an ongoing basis, articles in this series will explore topics such as value-based reimbursement, drug policy and pricing, balancing short-term access against long-term rates of innovation, and other relevant issues. Our goal is to create an open forum for sharing ideas and debating issues in these areas, extending the discussion to a broader audience.